TVRD

Tvardi Therapeutics, Inc.

Phase 2 AI-extracted

TTI-101

hepatocellular carcinoma (HCC)

Countdown

177days

Phase 2 readout · ~ Dec 31, 2026 estimated

What's at stake Phase 2 trial results for TTI-101 in hepatocellular carcinoma (HCC) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 14h ago

“Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) on track for 2H 2026”

Add to calendar Post on X Reddit

Provenance